rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits
None
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2013
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/43085 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: rhEPO for the Treatment of Erythropoietin Resistant Anemia in Hemodialysis Patients – Risks and Benefits
- Resistance to Recombinant Human Erythropoietin Therapy in Haemodialysis Patients
- Current Anemia Treatment in Hemodialysis Patients: The Challenge for Secure Use of Erythropoietin-Stimulating Agents
- Iron Deficiency in Hemodialysis Patients – Evaluation of a Combined Treatment with Iron Sucrose and Erythropoietin-Alpha: Predictors of Response, Efficacy and Safety
- Management of Anemia on Hemodialysis
- Artificial intelligence supported anemia control system (AISACS) to prevent anemia in maintenance hemodialysis patients
- Pharmacologic Adjuvants to Reduce Erythropoietin Therapy Dose in Anemia of Chronic Kidney Disease and End Stage Renal Disease